Bill Statistics
3
Actions
3
Cosponsors
0
Summaries
0
Subjects
1
Text Versions
Yes
Full Text
AI Summary
AI Summary
No AI Summary Available
Click the button above to generate an AI-powered summary of this bill using Claude.
The summary will analyze the bill's key provisions, impact, and implementation details.
Error generating summary
Latest Action
Oct 6, 2025
Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent.
Actions (3)
Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent.
Type: Floor
| Source: Senate
Oct 6, 2025
Passed/agreed to in Senate: Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent.
Type: Floor
| Source: Library of Congress
| Code: 17000
Oct 6, 2025
Introduced in Senate
Type: IntroReferral
| Source: Library of Congress
| Code: 10000
Oct 6, 2025
Cosponsors (3)
(D-NJ)
Oct 6, 2025
Oct 6, 2025
(R-ID)
Oct 6, 2025
Oct 6, 2025
(D-MD)
Oct 6, 2025
Oct 6, 2025
Full Bill Text
Length: 4,386 characters
Version: Agreed to Senate
Version Date: Oct 6, 2025
Last Updated: Nov 15, 2025 6:08 AM
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. Res. 436 Agreed to Senate
(ATS) ]
<DOC>
119th CONGRESS
1st Session
S. RES. 436
Expressing support for the designation of September 2025 as ``National
Prostate Cancer Awareness Month''.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
October 6, 2025
Mr. Crapo (for himself, Mr. Booker, Mr. Risch, and Mr. Van Hollen)
submitted the following resolution; which was considered and agreed to
_______________________________________________________________________
RESOLUTION
Expressing support for the designation of September 2025 as ``National
Prostate Cancer Awareness Month''.
Whereas more than 3,300,000 men are living with prostate cancer in the United
States;
Whereas 1 in 8 men in the United States will be diagnosed with prostate cancer
in their lifetimes and 1 in 41 men in the United States will die from
prostate cancer;
Whereas prostate cancer is the most commonly diagnosed non-skin cancer and the
second-leading cause of cancer-related deaths among men in the United
States;
Whereas the American Cancer Society estimates that, in 2025, 313,780 men will be
diagnosed with, and more than 35,770 men will die of, prostate cancer;
Whereas 35 percent of newly diagnosed prostate cancer cases occur in men under
the age of 65;
Whereas the odds of developing prostate cancer rise rapidly after age 50;
Whereas having a father or brother with prostate cancer more than doubles the
risk of a man developing prostate cancer, with a higher risk for men who
have a brother with the disease and the highest risk for men with
several affected relatives;
Whereas screening by a digital rectal examination and a prostate-specific
antigen blood test may be able to detect the disease at an early stage;
Whereas, when diagnosed with localized- or regional-stage prostate cancer, the
survival rate nears 100 percent;
Whereas only 37 percent of men survive more than 5 years if diagnosed with
prostate cancer after the cancer has metastasized;
Whereas there are typically no noticeable symptoms of prostate cancer in the
early stages, making discussions with a doctor regarding appropriate
screening critical;
Whereas, in fiscal year 2025, Congress appropriated $48,551,000,000 to the
National Institutes of Health, including $7,220,000,000 for the National
Cancer Institute;
Whereas, in fiscal year 2025, Congress appropriated $75,000,000 for the Prostate
Cancer Research Program of the Department of Defense;
Whereas the Department of Veterans Affairs has established 21 Precision Oncology
Centers of Excellence in order to deliver precision oncology services to
veterans suffering from prostate cancer;
Whereas ongoing research promises further improvements in prostate cancer
prevention, early detection, and treatment; and
Whereas educating individuals in the United States, including health care
providers, about prostate cancer and early detection strategies while
emphasizing the importance of consultation with a physician regarding
the benefits and risks of screening is essential to saving lives and
preserving and protecting families: Now, therefore, be it
Resolved, That the Senate--
(1) expresses support for the designation of ``National
Prostate Cancer Awareness Month'';
(2) declares that steps should be taken--
(A) to raise awareness about the importance of
screening methods for, and treatment of, prostate
cancer;
(B) to encourage research--
(i) to improve screening and treatment for
prostate cancer;
(ii) to discover the causes of prostate
cancer; and
(iii) to develop a cure for prostate
cancer; and
(C) to continue to consider ways to improve access
to, and the quality of, health care services for
detecting and treating prostate cancer; and
(3) calls on the people of the United States, interest
groups, and affected persons--
(A) to promote awareness of prostate cancer;
(B) to take an active role in the fight to end the
devastating effects of prostate cancer on individuals,
families, and the economy; and
(C) to observe National Prostate Cancer Awareness
Month with appropriate ceremonies and activities.
<all>
[From the U.S. Government Publishing Office]
[S. Res. 436 Agreed to Senate
(ATS) ]
<DOC>
119th CONGRESS
1st Session
S. RES. 436
Expressing support for the designation of September 2025 as ``National
Prostate Cancer Awareness Month''.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
October 6, 2025
Mr. Crapo (for himself, Mr. Booker, Mr. Risch, and Mr. Van Hollen)
submitted the following resolution; which was considered and agreed to
_______________________________________________________________________
RESOLUTION
Expressing support for the designation of September 2025 as ``National
Prostate Cancer Awareness Month''.
Whereas more than 3,300,000 men are living with prostate cancer in the United
States;
Whereas 1 in 8 men in the United States will be diagnosed with prostate cancer
in their lifetimes and 1 in 41 men in the United States will die from
prostate cancer;
Whereas prostate cancer is the most commonly diagnosed non-skin cancer and the
second-leading cause of cancer-related deaths among men in the United
States;
Whereas the American Cancer Society estimates that, in 2025, 313,780 men will be
diagnosed with, and more than 35,770 men will die of, prostate cancer;
Whereas 35 percent of newly diagnosed prostate cancer cases occur in men under
the age of 65;
Whereas the odds of developing prostate cancer rise rapidly after age 50;
Whereas having a father or brother with prostate cancer more than doubles the
risk of a man developing prostate cancer, with a higher risk for men who
have a brother with the disease and the highest risk for men with
several affected relatives;
Whereas screening by a digital rectal examination and a prostate-specific
antigen blood test may be able to detect the disease at an early stage;
Whereas, when diagnosed with localized- or regional-stage prostate cancer, the
survival rate nears 100 percent;
Whereas only 37 percent of men survive more than 5 years if diagnosed with
prostate cancer after the cancer has metastasized;
Whereas there are typically no noticeable symptoms of prostate cancer in the
early stages, making discussions with a doctor regarding appropriate
screening critical;
Whereas, in fiscal year 2025, Congress appropriated $48,551,000,000 to the
National Institutes of Health, including $7,220,000,000 for the National
Cancer Institute;
Whereas, in fiscal year 2025, Congress appropriated $75,000,000 for the Prostate
Cancer Research Program of the Department of Defense;
Whereas the Department of Veterans Affairs has established 21 Precision Oncology
Centers of Excellence in order to deliver precision oncology services to
veterans suffering from prostate cancer;
Whereas ongoing research promises further improvements in prostate cancer
prevention, early detection, and treatment; and
Whereas educating individuals in the United States, including health care
providers, about prostate cancer and early detection strategies while
emphasizing the importance of consultation with a physician regarding
the benefits and risks of screening is essential to saving lives and
preserving and protecting families: Now, therefore, be it
Resolved, That the Senate--
(1) expresses support for the designation of ``National
Prostate Cancer Awareness Month'';
(2) declares that steps should be taken--
(A) to raise awareness about the importance of
screening methods for, and treatment of, prostate
cancer;
(B) to encourage research--
(i) to improve screening and treatment for
prostate cancer;
(ii) to discover the causes of prostate
cancer; and
(iii) to develop a cure for prostate
cancer; and
(C) to continue to consider ways to improve access
to, and the quality of, health care services for
detecting and treating prostate cancer; and
(3) calls on the people of the United States, interest
groups, and affected persons--
(A) to promote awareness of prostate cancer;
(B) to take an active role in the fight to end the
devastating effects of prostate cancer on individuals,
families, and the economy; and
(C) to observe National Prostate Cancer Awareness
Month with appropriate ceremonies and activities.
<all>